Syndax’s Revuforj Shows Positive Results in AUGMENT-101 Clinical Trials For Acute Myeloid Leukaemia

Syndax Pharmaceuticals, a biopharmaceutical company focused on innovative cancer treatments. The firm has announced additional positive results from its ongoing trials for Revuforj® (revumenib). The AUGMENT-101 trial is evaluating Revuforj in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) harbouring mutant NPM1 (mNPM1). Meanwhile, the BEAT AML trial is testing Revuforj in combination with venetoclax and azacitidine in newly diagnosed AML patients.

Michael A. Metzger, Chief Executive Officer of Syndax, said in a statement, "These new data continue to highlight the exciting potential for Revuforj as both a monotherapy and in combination with other therapies. The recent approval of Revuforj for R/R acute leukaemia with a KMT2A translocation, coupled with the consistency of the results we have reported across KMT2Ar and mNPM1 within the different trials populations, continues to bolster our confidence in its practice-changing and blockbuster potential."

Revuforj, an oral and first-in-class menin inhibitor, is already FDA-approved for treating R/R acute leukaemia in patients with a lysine methyltransferase 2A (KMT2A) gene translocation. The approval includes adult and pediatric patients aged one year and older. These new findings further highlight Revuforj’s potential to address unmet needs in AML treatment.